• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers progress towards vaccine against fentanyl, heroin combo

August 21, 2017 By Sarah Faulkner

PillsResearchers reported at the 254th National Meeting & Exposition of the American Chemical Society today that they are developing a vaccine to guard against the effects of fentanyl in combination with heroin – a deadly duo that is claiming a growing number of lives as the opioid crisis worsens in the U.S.

“There is an urgent need to discover effective medications to treat substance use disorders. Increasingly, drug users are turning to opioids and powerful synthetic versions of these drugs that can sometimes be as much as 100 times more potent than heroin,” lead researcher Kim Janda said in prepared remarks. “Moreover, many patients receiving treatment relapse.”

Combating opioid use with a vaccine is challenging, since the immune system struggles to detect small molecules. Traditionally, scientists have overcome this problem by linking opioids to a larger biological molecule, like a protein.

Researchers at the Scripps Research Institute said that they have developed a vaccine that works against fentanyl and are developing a combination vaccine.

In June, Janda and his team of scientists reported developing a vaccine against heroin that proved effective in a monkey model.

Traditionally, treatment for people abusing opioids involves methadone – a therapy designed to block a person’s opioid receptors and stop heroin from binding to it. In contrast, the researchers’ vaccine triggers the production of antibodies, which bind to the heroin molecule and prevent it from ever getting to the opioid receptor.

The vaccine is specific for heroin and doesn’t work for other opioids, according to the researchers, so it could be used in combination with methadone.

The immunotherapeutic product is still far from hitting the market. But as the opioid crisis continues to intensify within the U.S., the need for innovative solutions becomes more urgent.

Earlier this month, President Donald Trump said that he is preparing to declare the opioid epidemic a national emergency. This is a reversal from an announcement made earlier this month by Health and Human Services Secretary Tom Price, who said that they would not make such a move.

“The opioid crisis is an emergency, and I’m saying officially right now it is an emergency,” Trump reportedly said, according to The Hill. “It’s a national emergency. We’re going to spend a lot of time, a lot of effort and a lot of money on the opioid crisis.”

But since Trump made the announcement, he has not taken any formal action to declare a national emergency.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2.

Filed Under: Featured, Pain Management, Pharmaceuticals, Research & Development Tagged With: scrippsresearchinstitute

IN CASE YOU MISSED IT

  • Go-Pen wins CE mark for user-fillable insulin pen
  • Tandem wins FDA nod to pair Mobi pump with Android smartphones
  • The top CGM stories of 2025
  • Billie Jean King supports Medtronic Diabetes awareness initiative
  • Tandem stock rises after hours on Q3 beats, record sales

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS